Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "pharmaceuticals"

1850 News Found

FDA greenlights Biocon’s Liraglutide for chronic weight management
News | February 25, 2026

FDA greenlights Biocon’s Liraglutide for chronic weight management

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management


Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation
R&D | February 24, 2026

Boehringer Ingelheim India and NIPER Raebareli join forces to boost pharma innovation

The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies


FDA accepts Teva’s NDA for long-acting schizophrenia injection
Drug Approval | February 21, 2026

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations


BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research
Clinical Trials | February 20, 2026

BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research

The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies


Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
News | February 19, 2026

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar


FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
Drug Approval | February 18, 2026

FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma

The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma


Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Clinical Trials | February 17, 2026

Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD

Duvakitug was well tolerated and safety was consistent with the induction study


Indian pharma market grew 10.2% yoy in January 2026
News | February 17, 2026

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise